Related Experiment Video
Updated: Sep 11, 2025

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
Starch Biopolymer Functionalized with Ipomoea batatas Extract: A Natural System for Bioactive Delivery in Type II
Brenda Avelina Lopez Muñiz1, Rosa Martha Perez Gutierrez2, Alethia Muñiz-Ramirez3
1Autonomous University of San Luis Potosí, Faculty of Chemical Sciences, Martínez 6, Dr. Manuel Nava Avenue, University Zone, Zip Code 78210, San Luis Potosí, S.L.P., Mexico.
Introduction:
Type 2 diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia. Natural compounds derived from plants, such as Ipomoea batatas, have shown therapeutic potential for its treatment.
Methods:
A starch-based biopolymer was developed and functionalized with a methanolic extract of Ipomoea batatas (IBM). Its physicochemical properties, such as swelling capacity, encapsulation efficiency, and extract release, were evaluated. In vivo tests were conducted on diabetic Danio rerio using two administration routes: immersion and oral delivery.
Results:
The biopolymer exhibited a swelling capacity of 333.03% and an encapsulation efficiency of 47.78%. In the zebrafish model, significant reductions in glucose, triglycerides, and cholesterol levels were observed, along with inhibition of advanced glycation end products (AGEs) formation in groups treated with IBM and BP-IBM.
Discussion:
The results suggest that the biopolymer preserves the chemical integrity of the extract and improves its bioavailability, enabling a significant therapeutic effect. The dual administration routes provide flexibility and demonstrate the efficacy of the delivery system.
Conclusion:
The starch-based system functionalized with I. batatas extract proved to be a promising and non-toxic platform for the delivery of bioactive metabolites in type 2 diabetes models, with potential for future therapeutic applications.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

